Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

BUY Ipca Laboratories - Q4FY22 Result Update - Weak exports; gradual recovery

Posted On: 2022-06-18 12:21:40 (Time Zone: IST)

Mr. Param Desai Research Analyst at Prabhudas Lilladher Pvt. Ltd.

Quick Pointers:

- Guided 10-12% revenue growth and 22-22.5% OPM for FY23.

- Added 1200 MRs in domestic formulation biz; launching 4 new divisions.

IPCA Lab's (IPCA) Q4 performance was impacted by weak exports, however API, UK and branded generics issues should normalize from H2FY23, in our view. Domestic business (45% of total sales) remained strong and it will continue to outperform IPM. Strong API capabilities and diversified model have benefited IPCA in the current environment. Our FY23E and FY24E EBIDTA stands reduced by 3% yet PAT cut is higher by 7-10%, as management indicated 25% tax rate vs 22-23% earlier. We recommend 'Buy' rating with revised TP of Rs 1,085 based on 23x FY24E earnings.

In-line revenues; weak export sales: IPCA's sales grew 16% YoY at Rs 12.9bn, in line with our estimates. Domestic business grew strongly 27% YoY, while export formulation remained weak with 3% YoY (flat QoQ) growth. Institutional business was up by mere 5% YoY lower than our est, due to lower order offtake. Branded and generics business were up by 2% YoY. Export API declined by 19% QoQ due to lower sales from Sartans and sales return. Domestic API grew by 52% YoY. Revenue from subsidiaries in Q4 came in at Rs 1.2bn.

Healthy GM; higher other expenses EBITDA margins came at 17.2%- down 365bps QoQ impacted by negative operating leverage. There were one-time impairment charges to tune of Rs225mn. Adj for this OPM came in at 19%. Gross margins were at 66.9% (PL est 65%) in Q4- up 180bps QoQ, mainly on better product mix. There was forex loss of Rs20m. Adj for forex, overheads grew 14% YoY led by higher freight cost. Staff cost also grew by 16% YoY led by higher provision of incentives to field staff. PAT declined by 19% YoY to Rs 1.3bn vs our est of Rs1.4bn.

Key Concall takeaways: (1) Though company has resolved the issue of Azido impurity and Sartan, growth is expected to be gradual and should normalize from Q2FY23 (2) Guided for 68-69% GM in FY23 on standalone nos (3) Institution business continued to be impacted due to lower order offtake and guided for flat revenue growth in FY23. (4) UK business to remain muted in FY23; targeting more registrations and commercialization of product on own labels (so far done 7 -8 registrations out of 44). During Q4 sales from UK were down to Rs200mn vs Rs600mn in Q4FY21 (5) Ipca will be adding 1200 MRs to 6000 for domestic formulation biz in FY23, which may result in higher employee cost. Guided for 12-13% growth in Domestic formulation biz in FY23 (6) API biz- Benefit from Dewas plant commercialization will be seen from Q2FY24. Will regain Sartan biz gradually. Guided for 10% growth in API business in FY23 (7) Higher inventory as of FY22, in order to avoid any supply disturbances due to China issues (8) Minimal impact of Russia issues to branded generics biz; Guided for 20% growth in FY23.

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

CRISIL Ratings: Steady demand to power up revenue of battery makers by 10-11%

Elevated gold prices to restrain jewellery consumption growth to 6-8% in FY2025: ICRA

Elara Securities India - Diet Report - Ambuja Cements - Cash deployment starts

Kotak Institutional Equities - Consumer Staples: Month in review: May 2024

Elara Securities India - Banking & Financials - Retail loans to MFI borrower a risky affair - Sector Update

Kotak institutional Equities - Real Estate: Hitting the Billion Mark

CRISIL Ratings: Tide turns for ship recyclers, revenue seen rising ~15% this fiscal

Elara Securities India - Diet Report - Media & Entertainment - Wait turns longer for occupancy revival

Elara Securities India - Economics - India: CPI inflation continues to ease

Kotak Institutional Equities - ESG, Global carbon pricing trends 2023: Needs more ambition

Kotak Institutional Equities - Economy: Inflation remains steady in May

Kotak Institutional Equities - Strategy: NTPC and PWGR are neither growth nor value stocks

Elara Securities India: Automobiles - Tata Motors - Aggressive PV market share target - Company Update - Accumulate - TP: INR 1,100 - Upside: 11%

Finance Companies - Gold lending in the spotlight - Report by InCred Equities

CRISIL Ratings: Revenues of shrimp exporters to grow 8-10% as demand improves

Elara Securities India: Utilities & Renewables - Peak demand ascends to record highs - Monthly Update

Tata Motors - Analyst meet highlights - REDUCE - Maintained - Report by InCred Equities

Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum

Elara Securities India - Metals & Mining - Input cost inches up - Monthly Update

CRISIL Ratings: Paints sector to double production capacity by fiscal 2027

Elara Securities India-Economics - India: Smooth sailing into H2CY24

Kotak Institutional Equities - Insurance, NoP drives APE growth for private players

Financial Services - AMCs - Election month propels equity fund inflow - Report by InCred Equities

Kotak Institutional Equities - Strategy: Fight, flee or join a stampede?

Elara Securities India - Utilities - PTC India - Trading volumes up by 10% in Q4 - Q4FY24 Update - Reduce - TP INR 207 - Upside: 1%

Kotak Institutional Equities - Economy: Coalition journey: Long travails ahead

Kotak Institutional Equities - IT Services: CTSH-big bet in core engineering services

Elara Securities India - Initiating Coverage - Infrastructure - Hindustan Construction - Phoenix Rises - Buy - TP INR 63 - Upside: 65%

Elara Securities India - Real Estate - Oberoi Realty - Low-risk compounder - Company Update - Buy - TP: INR 2,350 - Upside: 24%

Elara Securities India - Diet Report - Aviation - INDIGO: lagging fleet growth vs rivals

Elara Securities India - The IT Inflexion Point - Market Internals with Biju Samuel - Quantitative & Alternate Strategy

Elara Securities India - Economics - RBI Policy: Nascent rate cut discussions

Elara Securities India-Diet Report - Internet - JioMart to enter qCommerce - execution is key

Elara Securities India-India Strategy - Exit Polls: Doubt over long term sustainable rally

FY2025 domestic steel consumption growth revised upwards to 9-10%: ICRA

Elara Securities India-Strategy - Q4FY24 Review - Ending FY24 on good note

Elara Securities India-Banking & Financials - Services lifts growth; unsecured growth softens - Sector Update

Elara Securities India-Healthcare - Apollo Hospitals Enterprise - New beds impacting margin - Q4FY24 Update/Rating Change - Accumulate - TP INR 6,183 - Upside: 6%

Elara Securities India-Economics - India GDP: Upside surprise continues

Elara Securities India-Banking & Financials - Rules-based credit model shows vulnerability - Sector Update

Elara Securities India-Oil & Gas - Gujarat Gas - Play on LNG surplus, rise in propane prices - Company Update - Buy - TP INR 745 - Upside: 35%

Elara Securities India-FMCG - Mrs Bectors Food Specialities - New capacity and innovation, key drivers - Q4FY24 Update/Rating change - Accumulate - TP INR 1,414 - Upside: 12%

Kotak Institutional Equities - Diversified Financials: Regulating retail F&O: Global learnings and potential options

Kotak Institutional Equities - Automobiles & Components: 4QFY24 review - Sustaining momentum

Strategy: Exit polls 2024: No Drama by Kotak Institutional Equities

Elara Securities India - Global Liquidity Tracker: Inflows into India Dedicated Largecap funds continued ahead of Election results. China flows again turn weak

Elara Securities India-Banking & Financials - Attention - Still a lot on RBI's radar - Sector Update

Indo Count Industries- Bumpy Quarter; Smooth Road Ahead - Share India Securities

Elara Securities India-Auto Ancillaries - Amara Raja Energy & Mobility - All eyes on tech partner for Li-ion cells - Q4FY24 Update/Target price change - Accumulate - TP INR 1,341 - Upside: 13%

Flair Writing Industries Ltd - Steady margins in competitive industry - Share India Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020